Elicio Therapeutics

Elicio Therapeutics is a clinical-stage biotechnology company dedicated to engineering lymph node-targeted immunotherapies to treat aggressive cancers and infectious diseases. Their innovative approach focuses on harnessing the natural power of the lymph nodes, the "command center" of the immune system, to amplify the body's immune response against tumors. They are developing next-generation vaccines, immunomodulators, and adjuvants using their Amphiphile (AMP) platform, which delivers therapeutic payloads directly to the lymph nodes, enhancing the activation and function of cancer-fighting T cells.

Elicio's lead candidate, ELI-002, is a lymph node-targeted mutant Kirsten rat sarcoma (mKRAS) cancer vaccine designed to target the most common KRAS mutations that drive 25% of all solid tumors. They are also developing ELI-007 and ELI-008, which target BRAF and p53 hotspot mutations respectively, to address a broad spectrum of cancers with high unmet need. Elicio's mission is to empower patients to fight cancer with full force by amplifying the potential of immunotherapies.

Elicio Therapeutics values a healthy and sustainable work-life balance for its employees. While specific details about job flexibility are not mentioned in the provided website content, the company's commitment to work-life balance suggests that they are open to exploring flexible work arrangements to accommodate the needs of their employees.

Elicio Therapeutics is a clinical-stage biotechnology company developing investigational lymph node-targeted vaccines for a range of aggressive cancers and infectious diseases. Their mission is to harness the natural power of the lymph nodes, the body's "command center" of the immune system, to amplify immune responses against tumors. They aim to achieve this by using their proprietary Amphiphile (AMP) platform to deliver therapeutic payloads directly to the lymph nodes, enhancing the body's cancer-fighting mechanisms and potentially improving patient outcomes.

Elicio Therapeutics fosters a collaborative and supportive culture that prioritizes teamwork, inclusivity, and a shared passion for developing life-changing therapies. The company believes in the power of collective effort, encouraging open communication and diverse perspectives. Elicio values integrity, excellence, and a commitment to making a positive impact on the lives of cancer patients. They also emphasize work-life balance, creating a sustainable and rewarding environment for their employees.

Elicio Therapeutics values inclusivity and fosters a diverse and respectful workplace. They believe that a varied team with different perspectives and backgrounds is essential for achieving success in their mission of developing life-changing therapies for cancer patients. The company prioritizes creating an environment where all voices are heard, and team members are supported, empowered, and encouraged to grow and innovate. This commitment to diversity, equity, and inclusion is reflected in their company values of tenacity, inclusivity, and compassionate care.